罗沙司他对维持性血液透析合并肾性贫血患者的疗效分析

Efficacy Analysis of Roxadustat on Maintenance Hemodialysis Patients with Renal Anemia

目的探究维持性血液透析合并肾性贫血患者采用罗沙司他治疗的临床疗效。方法将2020年4月—2021年4月江苏省泗洪分金亭医院收治的83例维持性血液透析合并肾性贫血患者视为研究对象,以随机数表法分为两组,对照组患者41例采用重组人促红细胞生成素进行治疗,观察组患者42例采用罗沙司他进行治疗。对比两组治疗前后铁代谢指标、贫血指标变化情况、不良反应发生情况。结果观察组治疗后血红蛋白(Hb)、血细胞比容(Hct)、总铁结合力(TIBC)、转铁蛋白饱和度(TSAT)、转铁蛋白(TRF)水平分别为(111.25±3.19)g/L、(32.98±2.26)%、(45.18±3.28)μmol/L、(18.89±4.09)%、(289.96±3.63)mg/dl,均高于对照组,差异有统计学意义(t=27.110、15.185、13.871、3.525、86.029,P<0.05);观察组不良反应发生率为7.14%,低于对照组的24.39%,差异有统计学意义(χ^(2)=4.672,P<0.05)。结论维持性血液透析合并肾性贫血患者采用罗沙司他治疗的临床疗效显著,可改善机体铁代谢与贫血状况,且不良反应发生率低,治疗安全性高。

Objective To investigate the clinical efficacy of roxadustat in the treatment of maintenance hemodialysis patients with renal anemia.Methods A total of 83 patients with maintenance hemodialysis complicated with renal anemia who were treated in Sihong Fenjinting Hospital of Jiangsu Province from April 2020 to April 2021 were re⁃garded as the research objects,and were divided into two groups by random number table method.The control group of 41 patients,Genitin was used for treatment,and 42 patients in the observation group were treated with roxadustat.The changes of iron metabolism indexes,anemia indexes,and adverse reactions were compared between the two groups before and after treatment.Results The levels of hemoglobin(Hb),hematocrit(Hct),total iron binding capac⁃ity(TIBC),transferrin saturation(TSAT),transferrin(TRF)in the observation group were(111.25±3.19)g/L,(32.98±2.26)%,(45.18±3.28)μmol/L,(18.89±4.09)%,(18.89±4.09)%,(289.96±3.63)mg/dL,which were higher than those in the control group,and the difference was statistically significant(t=27.110,15.185,13.871,3.525,86.029,P<0.05).The incidence of adverse reactions in the observation group was 7.14%,which was lower than 24.39%in the control group,and the difference was statistically significant(χ^(2)=4.672,P<0.05).Conclusion The clinical efficacy of roxadustat in maintenance hemodialysis patients with renal anemia is significant,and it can improve iron metabo⁃lism and anemia.The incidence of adverse reactions is low,and the treatment is safe.